Namzaric
Designed to target cognitive decline and indicated to support memory and function, this medication is utilized to alleviate symptoms of dementia.
Strengths: 5/5mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Cognitive enhancer
- Pharmacological class
Acetylcholinesterase inhibitor; NMDA receptor antagonist
- Contraindications
hypersensitivity to components; severe hepatic impairment; uncontrolled epilepsy
- Minor side effects
nausea; diarrhoea; dizziness
- Moderate side effects
insomnia; anaemia; fatigue
- Dosage forms
Capsule
- Administration route
Oral use
- Prescription status
POM
- Onset Time
4–6 weeks
- Duration
long-term
- Storage instructions
Store at controlled room temperature.
- Drug interactions
anticholinergics; succinylcholine; beta-blockers
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Use only if indicated. Breastfeeding: Not recommended.
Precautions and warnings
use with caution in cardiac conduction disorders; monitor for gastrointestinal distress; may worsen asthma or chronic obstructive pulmonary disease
Serious side effects
bradycardia — requires immediate medical attention; seizures — requires immediate medical attention; peptic ulcer — requires immediate medical attention
Patient summary
Designed to target cognitive decline and indicated to support memory and function, this medication is utilized to alleviate symptoms of dementia.
Mechanism of action
Namzaric combines an acetylcholinesterase inhibitor (donepezil), which increases acetylcholine availability, with an NMDA receptor antagonist (memantine), which modulates glutamate activity to protect neurons from excitotoxicity, providing dual-action neuro-support.
Namzaric
Designed to target cognitive decline and indicated to support memory and function, this medication is utilized to alleviate symptoms of dementia.
Editorial Notes
- Active ingredient(s): Donepezil, Memantine
- Listed indication(s): Alzheimer’s Disease
Available option
- 60 tablets - 5/5 mg1441-5-5-mg-17413